Fluvastatin as Co-Medication in Heart Transplant Recipients With Elevated Creatine-Kinase

Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report

“…Herein we report the case of a patient receiving fluvastatin for several years developing mild myotoxicity symptoms after co-administration of telmisartan, an AT1-receptor antagonist. Importantly, fluvastatin even if exhibiting a rather modest lipid-lowering effect has been widely recommended for patient receiving pharmacotherapy with high interaction potential due to the assumed low risk of pharmacokinetic interaction [ 1 ]. It was aim of this retrospective pharmacogenetic analysis to provide insight into genetic risk factors for the observed drug-drug interaction.…”

Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study

“…12 Fluvastatin, conversely, does not interact with the cytochrome CYP3A4, 12 and has been tested in a large, multicenter study on kidney transplant recipients. 13 Although it appears to safely overcome the side effects of more potent compounds, 14 its efficacy and possible graftrelated effects after HT remain largely unexplored.…”

Rhabdomyolysis after Transplantation: Case Report after Allogeneic Hematopoietic Transplantation and Review of Literature

“…It is also unaffected by OATP1B1, and thus AUC of fluvastatin is not affected by cyclosporine. Therefore, fluvastatin may be a safer choice for patients treated with cyclosporine who need a statin [56]. Other agents that may be safe to use for hyperlipidemia in cases requiring concomitant cyclosporine treatment are fibrate and niacin [53].…”